OutSee has secured £2.5 million in seed funding as the genomics and drug discovery company accelerates development of its AI-driven predictive genomics platform, Nomaly.

The round was led by Ahren Innovation Capital with support from Kadmos Capital, Panacea, Empirical Ventures and 26 angel investors, and will be used to advance a pipeline of data-backed therapeutic targets through experimental validation.

Alongside the raise, the Cambridge-headquartered MedTech has signed a strategic agreement with preclinical CRO o2h discovery to launch a collaborative drug discovery programme for its lead target, supported by o2h’s InflexionTx co-discovery funding model.